Adrian H Heald1,2, Michael Stedman3, Linda Horne4, Rustam Rea5, Martin Whyte6, J Martin Gibson1,2, Simon G Anderson7,8, Willam Ollier9. 1. The School of Medicine, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. 2. Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK. 3. Res Consortium, Andover, UK. 4. Vernova Healthcare, Watersgreen Medical Centre, Macclesfield, UK. 5. Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS FT, Oxford, UK. 6. Department of Clinical & Experimental Medicine, University of Surrey, Guildford, UK. 7. University of the West Indies, Cavehill Campus, Bridgetown, Barbados. 8. Division of Cardiovascular Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK. 9. Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.
Abstract
AIMS: Evidence suggests that some people with type 1 diabetes mellitus (T1DM) experience temporary instability of blood glucose (BG) levels after COVID-19 vaccination. We aimed to assess this objectively. METHODS: We examined the interstitial glucose profile of 97 consecutive adults (age ≥ 18 years) with T1DM using the FreeStyle Libre® flash glucose monitor in the periods immediately before and after their first COVID-19 vaccination. The primary outcome measure was percentage (%) interstitial glucose readings within the target range 3.9-10 mmol/L for 7 days prior to the vaccination and the 7 days after the vaccination. Data are mean ± standard error. RESULTS: There was a significant decrease in the % interstitial glucose on target (3.9-10.0) for the 7 days following vaccination (mean 52.2% ± 2.0%) versus pre-COVID-19 vaccination (mean 55.0% ± 2.0%) (p = 0.030). 58% of individuals with T1DM showed a reduction in the 'time in target range' in the week after vaccination. 30% showed a decrease of time within the target range of over 10%, and 10% showed a decrease in time within target range of over 20%. The change in interstitial glucose proportion on target in the week following vaccination was most pronounced for people taking metformin/dapagliflozin + basal bolus insulin (change -7.6%) and for people with HbA1c below the median (change -5.7%). CONCLUSION: In T1DM, we have shown that initial COVID-19 vaccination can cause temporary perturbation of interstitial glucose, with this effect more pronounced in people talking oral hypoglycaemic medication plus insulin, and when HbA1c is lower.
AIMS: Evidence suggests that some people with type 1 diabetes mellitus (T1DM) experience temporary instability of blood glucose (BG) levels after COVID-19 vaccination. We aimed to assess this objectively. METHODS: We examined the interstitial glucose profile of 97 consecutive adults (age ≥ 18 years) with T1DM using the FreeStyle Libre® flash glucose monitor in the periods immediately before and after their first COVID-19 vaccination. The primary outcome measure was percentage (%) interstitial glucose readings within the target range 3.9-10 mmol/L for 7 days prior to the vaccination and the 7 days after the vaccination. Data are mean ± standard error. RESULTS: There was a significant decrease in the % interstitial glucose on target (3.9-10.0) for the 7 days following vaccination (mean 52.2% ± 2.0%) versus pre-COVID-19 vaccination (mean 55.0% ± 2.0%) (p = 0.030). 58% of individuals with T1DM showed a reduction in the 'time in target range' in the week after vaccination. 30% showed a decrease of time within the target range of over 10%, and 10% showed a decrease in time within target range of over 20%. The change in interstitial glucose proportion on target in the week following vaccination was most pronounced for people taking metformin/dapagliflozin + basal bolus insulin (change -7.6%) and for people with HbA1c below the median (change -5.7%). CONCLUSION: In T1DM, we have shown that initial COVID-19 vaccination can cause temporary perturbation of interstitial glucose, with this effect more pronounced in people talking oral hypoglycaemic medication plus insulin, and when HbA1c is lower.
Authors: Gabriella di Mauro; Annamaria Mascolo; Miriam Longo; Maria Ida Maiorino; Lorenzo Scappaticcio; Giuseppe Bellastella; Katherine Esposito; Annalisa Capuano Journal: Pharmaceuticals (Basel) Date: 2022-05-27
Authors: Marco Infante; Andrea Fabbri; Nathalia Padilla; Francesca Pacifici; Pasquale Di Perna; Laura Vitiello; Alessandra Feraco; Maria Giuliano; Marina Passeri; Massimiliano Caprio; Camillo Ricordi; David Della-Morte; Luigi Uccioli Journal: Vaccines (Basel) Date: 2022-07-08